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Decreased Immunoreactivity of CD99 Is an Independent
Predictor of Regional Lymph Node Metastases in
Pulmonary Carcinoid Tumors
Giuseppe Pelosi, MD, MIAC,*§ Maria Elena Leon, MPH, ScD, BSc,† Giulia Veronesi, MD,‡
Lorenzo Spaggiari, MD,‡ Felice Pasini, MD, and Giuseppe Viale, MD, FRCPath*§
Background: Few data are available on the prevalence and clini-
copathological meaning of CD99, the transmembrane product of the
pseudoautosomal MIC2 gene, in pulmonary neuroendocrine tumors.
Methods: We evaluated CD99 immunoreactivity in lung tissues,
pulmonary neuroendocrine hyperplasias, and 136 consecutive pul-
monary neuroendocrine tumors of diverse histological types.
Results: By immunohistochemistry, a membranous and/or cytoplas-
mic immunoreactivity was seen in 60 of 136 (44%) tumors, whereas
both normal and hyperplastic neuroendocrine cells of the lung were
consistently nonreactive. A steady decrease of the CD99 labeling
index was observed from better to poorly differentiated tumors, with
a prevalence of the membranous pattern in typical carcinoids (TCs),
and of the cytoplasmic pattern in atypical carcinoids (ACs) and large
cell neuroendocrine carcinoma/small cell lung carcinoma (P 
0.0001), independent of tumor stage. In TCs/ACs, increased levels
of CD99 labeling index or the membranous pattern were associated
with low proliferative fraction (P  0.0011) and smaller tumor size
(P 0.0054) and with lack of regional lymph node metastases (P
0.0078). Moreover, CD99 expression decreased according to the
pN0-2 classes (P  0.0016), with an inverse relationship between
the number of positive lymph nodes, the labeling index (P  0.013)
and the nonmembranous pattern (P  0.016). At multivariate
analysis, both the decreased CD99 labeling index and the negative/
cytoplasmic staining were independent risk indicators for lymph
node metastases in the subset of TC/AC patients. No relevant
relationships were found in large cell neuroendocrine carcinoma/
small cell lung carcinoma.
Conclusion: CD99 is especially present in low- to intermediate-
grade neuroendocrine tumors of the lung, and loss of the marker
correlates with the occurrence of nodal metastases in TC/AC pa-
tients.
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The cell surface molecule CD99, also known as E2, 12E7,HuLy-m6, and FMC29,1–4 is a heavily O-glycosylated Mr
32,000 glycoprotein encoded by the MIC-2 gene, which is
mapped to the pseudoautosomal regions of both human Xp
and Yp chromosomes.5–9 The MIC-2 gene includes 10 exons
encoding for an integral membrane protein with a single
transmembrane region, an extracellular amino terminus, and
a cytosolic carboxy terminus8,10–12 that is constitutively ex-
pressed on the erythrocyte surface in most individuals.13 The
MIC-2 locus on chromosome Xp is not subject to inactiva-
tion,14 and its gene product shares no homology with any
known protein, with the exception of the XG (also called
PBDX) blood group gene product (48% homologous to
CD99) mapping to the same chromosomal region.10,15–18
Although originally thought to be a specific marker of
Ewing’s sarcoma/peripheral primitive neuroectodermal tu-
mor (PNET),18–21 CD99 expression has now been demon-
strated in a wider range of normal1,3,10,15,22–28 and neoplas-
tic9,29–41 human tissues, including epithelial tumors of the
ovary,42 breast,43 stomach,44 and some gastrointestinal9,45 and
pulmonary2,45 neuroendocrine tumors.
The specific functions of CD99 still remain largely
unknown, although this protein has been implicated in several
biological activities such as homophilic cell-cell adhesion
during hematopoiesis,1,46 binding of leukocytes to vascular
endothelial cells during the extravasation cascade,24,47,48 ap-
optosis of T lymphocytes49,50 and Ewing’s family tumor
cells,51 expression of several transmembrane and cytoplasmic
proteins,23–25,28,32,46,52,53 regulation of cell cycle and differen-
tiation,27,34,43,54 and modulation of the insulinlike growth
factor-I, insulin, and human growth hormone action.9,55
Neuroendocrine tumors of the lung are most commonly
classified according to a four-tiered classification system,
ranging from relatively indolent tumors with longer life
expectation (including typical [TC] and atypical [AC] carci-
noids) to very aggressive tumors with dismal prognosis (in-
cluding large cell neuroendocrine carcinoma [LCNEC] and
small cell lung carcinoma [SCLC]).56,57 The World Health
Organization/International Association of the Study of Lung
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Cancer provided in 2004 histological criteria for classifying
all the diverse histological types of neuroendocrine tumors,56
even though other different classification schemes have been
proposed.58,59 The greatest difficulty in all these proposals,
however, is to separate the subsets of patients with different
biological behavior within each diagnostic category, espe-
cially in the case of low- to intermediate-grade tumors that
collectively show a fairly better prognosis as compared with
the poorly differentiated tumors.
In the past, many investigations dealing with low- to
intermediate-grade tumors usually considered patient survival
as the main clinical outcome,60–70 whereas the role of factors
implicated in the development of metastasis to regional
lymph nodes has not been extensively investigated in these
tumors. In a small series of 31 neuroendocrine neoplasms of
the lung, we found that CD99 down-regulation was signifi-
cantly associated with increased risk of lymph node metas-
tases and, marginally, with reduced tumor cell proliferative
activity.45 However, the actual prevalence of CD99 expres-
sion and its clinicopathological implications have not been
widely investigated thus far in a large series of neuroendo-
crine proliferations including tumors of various histological
types.
This study was aimed at evaluating CD99 immunore-
activity in 136 pulmonary tumors encompassing the whole
spectrum of neuroendocrine neoplasms, as well as in normal
neuroendocrine cells of the respiratory epithelium and hyper-
plastic neuroendocrine tumorlets. Our results document that
CD99 down-regulation is an independent predictor of lymph
node metastasis only in patients with TC and AC.
PATIENTS AND METHODS
Patients
The study population includes 136 consecutive patients
(89 males and 47 females) with stage I to IIIB neuroendocrine
tumors (41 TCs, 26 ACs, 42 LCNECs, and 27 SCLCs)
surgically treated at the City Hospital in Verona and the
European Institute of Oncology in Milan, Italy, between 1987
and 2001. All tumors were pathologically staged according to
the international system for staging lung cancer.56 To ensure
accurate staging, all tumors were radically excised along with
an adequate number of local (N1) and mediastinal (N2)
lymph node (median value: nine lymph nodes per patient).
The paraffin sections of all cases were retrieved, and the
original hematoxylin and eosin–stained sections reviewed.
The relative prevalence of carcinoids, either typical or atyp-
ical, and of LCNECs over SCLCs (the latter usually account-
ing for at least 20% of all lung carcinomas considered as a
whole)56 is due to the fact that only surgically excised
specimens were used in the study.
The diagnosis of neuroendocrine tumor was based on
established morphological and immunohistochemical criteria
(immunoreactivity for synaptophysin, chromogranin A, and a
variety of respiratory tract–related hormones, including gas-
trin-related peptide, calcitonin, adrenocorticotropic hormone,
serotonin and -human chorionic gonadotropin.45,56,57,59
Because a large body of evidence supports that TCs and ACs
are genetically, pathologically, and clinically related and are
not precursors of poorly differentiated neuroendocrine tu-
mors,60–66,71–73 clinicopathological comparisons in this study
included two groups, i.e., patients having TC/AC and patients
having LCNEC/SCLC, respectively. TCs and ACs were con-
sidered together in the analysis because of the small number
of patients in each tumor group (41 for TCs and 26 for ACs,
respectively). Relevant information on the main differences
in the two tumor groups is provided in Table 1.
Follow-up information was available for 126 of 136
patients: 31 patients (24.6%) had recurrent disease and 25
(19.8%) of them died of disease. The follow-up time, how-
ever, was too short (mean  SD: 20.5  27.2 months;
median value: 11 months) at the time of the analysis to allow
a reliable survival analysis to be carried out. No patient
presented with endocrine symptoms due to hormone hyper-
production.
Immunocytochemical Assay
Formalin-fixed and paraffin-embedded tissue samples
obtained at surgery were investigated. Tumors up to 2 cm in
size were entirely embedded and immunostained; at least two
representative tissue blocks were investigated in larger neo-
plasms. Ten samples of normal pulmonary parenchyma and
bronchial tree taken at different levels from patients with
nonmalignant lung diseases, and 10 samples of pulmonary
neuroendocrine hyperplasias and nonneoplastic peritumoural
lung tissue from the study patients were used as control
groups for CD99 immunoreactivity.
Immunohistochemical reactions were performed using
the primary antibodies listed in Table 2. In particular, CD99
was immunolocalized with the monoclonal antibody H036-
1.1, raised against purified E-rosette–forming cells from hu-
man peripheral blood lymphocytes (Novocastra Laboratories,
TABLE 1. Differential Clinicopathological Features
Variable Category
TC/AC
( n  67)
LCNEC/SCLC
( n  69) P value
Age (yr) Median 55 64 0.0001
Gender (%) Male 32 (47.8) 57 (82.6)
Female 35 (52.2) 12 (17.4) 0.0001
Size (cm) Median 2.5 3.5 0.0005
Tumor stage (%) I 47 (70.2) 34 (49.3)
II–IIIB 20 (29.8) 35 (50.7) 0.0151
pT (%) T1 49 (73.1) 24 (34.8)
T2–T4 18 (26.9) 45 (65.2) 0.0001
LN metastasis (%) Absent 46 (68.7) 34 (49.28)
Present 21 (31.3) 35 (50.7) 0.0245
LN metastasis site (%) pN0 46 (68.7) 34 (49.3)
pN1 12 (17.9) 18 (26.1)
pN2 9 (13.4) 17 (24.6) NS
No. of positive LN Median 0 1 0.0053
Chromogranin A Median 95 15 0.0001
Synaptophysin Median 100 39 0.0001
Categorical variables are compared with Fisher’s exact t test or 2 test; continuous
variables with Wilcoxon’s two-sample test.
TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroendocrine
carcinoma; SCLC, small cell lung carcinoma; NS, not significant; LN, lymph node.
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Newcastle upon Tyne, UK). The specificity of this CD99
antibody was determined on a panel of normal and tumor
tissues, and results were compared with those of other pub-
lished studies using other CD99 clones (Novocastra Labora-
tories, personal communication). For the immunohistochem-
ical staining, after blocking endogenous peroxidase activity
with hydrogen peroxide and microwave antigen retrieval with
citrate buffer at pH6, the sections were reacted overnight at
4°C with the anti-CD99 antibody diluted 1:500 in buffer or
the other primary monoclonal antibodies at their optimal
dilution (Table 2), and then incubated with a commercially
available, highly sensitive detection kit (DAKO EnVision
Plus-HRP, Dakopatts, Glostrup, Denmark) following the
manufacturer’s instructions. Peroxidase activity was devel-
oped with 3,3=-diaminobenzidine (Sigma Chemical Co., St.
Louis, MO) and copper sulfate to obtain a brown-black end
product. The sections were eventually counterstained with
Harris’ hematoxylin. Paraffin sections of normal thymus and
a case of Ewing’s sarcoma, both known to be strongly
immunoreactive for CD99, were stained in parallel as exter-
nal positive controls. The specificity of all immunoreactions
was also double-checked, either substituting the primary
antibody with a nonrelated isotypic mouse immunoglobulin
at a comparable dilution or with normal serum alone.74
Evaluation of the Results
All cases were evaluated by an experienced lung cancer
pathologist (G.P.) blind to patient identity and stage of
disease. The percentage of CD99-immunoreactive tumor
cells (labeling index  number of CD99 immunoreactive
cells/total of counted cells) was assessed for every case
scanning at least 2,000 neoplastic cells in representative fields
of immunostaining. Also, the immunostaining pattern was
recorded, indicating whether pattern was either membranous
if a moderate to strong cytoplasmic decoration with variable
membrane reinforcement was seen in tumor cells or cytoplas-
mic if a granular dotting was confined to the cytoplasm
without appreciable membrane decoration. Tumors were con-
sidered negative if staining was either completely absent or
observed in 5% or less of neoplastic cells, independent of the
immunostaining pattern. Proliferative activity of tumor cells
was assessed by Ki-67 antigen immunoreactivity on consec-
utive paraffin sections, as described elsewhere in detail.45,75,76
Statistical Analysis
Qualitative data are presented as frequencies and per-
centages and compared using a 2 test (applying Yates’
correction for continuity) or Fisher’s exact test. Continuous
data were expressed using median values and contrasted
employing the Wilcoxon signed-rank test for pairs or the
Kruskal-Wallis test if medians were analyzed between two or
more groups. All correlation tests were performed using
Spearman’s rank test (r). The risk for regional lymph node
metastasis associated with CD99 expression, adjusting for
potential confounders (i.e., age, gender, and pathologic T
[pT] class), was analyzed using logistic regression (SAS,
Cary, NC) and described by the odds ratios (ORs) and
corresponding 95% confidence intervals (CIs). ORs were
calculated for CD99% divided into two groups by the me-
dian. Any statistical test was considered significant if the
corresponding P value was 0.05.
RESULTS
CD99 Immunoreactivity Is Consistently Lacking
in Normal and Hyperplastic Neuroendocrine
Cells of the Lung
All samples of normal pulmonary parenchyma and
bronchial tree from patients with nonmalignant lung diseases
and all samples of pulmonary neuroendocrine tumorlets and
nonneoplastic peritumoural lung tissue from the study pa-
tients were consistently nonreactive for CD99. Likewise,
surface ciliated and mucous cells of the bronchial epithelium,
seromucous glands of the bronchial wall, and pneumocytes
and Clara cells did not show any immunostaining.
CD99 Immunoreactivity Is Most Prevalent in
TCs/ACs
Overall, CD99 immunoreactive cells were found in 60
of 136 (44%) tumors, including 31 of 41 (75.6%) TCs, 14 of
27 (51.8%) ACs, 10 of 42 (23.8%) LCNECs, and five of 27
(18.5%) SCLCs (P  0.0001). A steady decrease of CD99
labeling index was observed from better to less differentiated
tumors (Table 3). In TCs, there was a higher prevalence of
moderate to strong membranous labeling in tumor cells,
whereas in immunoreactive ACs and LCNECs/SCLCs, the
TABLE 2. Antibody Panel Used in the Study
Antibodies m/p Clone Source Dilution Pretreatment
CD99 m HO36-1.1 Novocastra Laboratories, Newcastle upon Tyne, UK 1:500 MWO-CB
Chromogranin A m LK2H10 Signet Laboratories, Dedham, MA 1:40 None
-Human chorionic gonadotropin p — ‘ 1:200 MWO-CB
Synaptophysin m SY 38 DAKO, Glostrup, Denmark 1:20 MWO-CB
Gastrin-releasing peptide p — ‘ 1:400 None
Calcitonin p — ‘ 1:20 None
Serotonin m 5HT-H209 ‘ 1:10 None
ACTH m 02A3 ‘ 1:100 None
Ki-67 antigen m MIB-1 Immunotech, Marseille, France 1:400 MWO-EDTA
m/p, monoclonal/polyclonal; MWO-CB, microwave oven at 750 W for 10 minutes in citrate buffer, pH6; MWO-EDTA, microwave oven at 750 W for 12 minutes in
ethylenediamine tetraacetic acid buffer, pH 8; ACTH, adrenocorticotropic hormone.
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prevalent pattern was exclusively cytoplasmic (Table 3).
These differences in both CD99 labeling index and immuno-
staining pattern persisted after adjusting tumors for stage I
(P  0.01). Frequency distributions of CD99 labeling index
and immunostaining patterns in the whole series as a function
of tumor types (not stratified for stage of disease) are pro-
vided in Figure 1. Representative features of CD99 immuno-
staining in diverse tumor types are shown in Figure 2.
A strong correlation was found between CD99 labeling
index and immunostaining pattern in TCs (r  0.75), ACs
(r  0.71), LCNEC (0.92), and SCLC (0.77) (P  0.0001).
In particular, tumors expressing more than 45% CD99 im-
munoreactive cells (threshold corresponding to the median of
the positives in the whole series of tumors) showed a sharp
prevalence of membranous pattern (72%), whereas tumors
with 45% or less of positive cells mostly exhibited cytoplas-
mic pattern (81%) (P  0.0001). No preferential distribution
of CD99-immunoreactive cells was seen within individual
cases in perivascular, peripheral, or central viable areas of
tumor.
CD99 Expression Is Associated with Reduced
Proliferative Fraction, Small Tumor Size, and
Lack of Regional Lymph Node Metastases in
TCs/ACs
In TCs/ACs, increased (27% median value) CD99
labeling indexes or the membranous staining patterns were
preferentially observed in low proliferating stage I tumors of
small size, with low prevalence of regional lymph node
metastases (Table 4). On the contrary, either lower CD99
labeling index or negative to cytoplasmic immunostaining
patterns correlated significantly with the pN class and the
total number of positive lymph nodes as well as with a
decreased immunoreactivity for synaptophysin (Table 4).
These differences, however, disappeared after adjusting for
stage I of disease (37 cases I-A versus 10 cases I-B). More-
over, no association was noted with age, gender, pT class, and
respiratory tract-related hormone content in the same tumor
group, even after adjusting for tumor stage.
In LCNEC/SCLC, no correlations were found with any
of the tested clinicopathological variables, apart from a sta-
tistically significant reduced chromogranin A content in tu-
mors lacking CD99 expression (P  0.033).
CD99 Immunoreactivity Is an Independent
Predictor of Lymph Node Metastases in TC/AC
Lymph node metastases were significantly more com-
mon in LCNEC/SCLC (50.7%) than in TCs/ACs (31.3%)
(Table 1). This difference, however, did not occur in both
genders: in males, it disappeared (42% versus 28%, respec-
tively, P  0.19), and in females was actually accentuated
(92% versus 34%, P  0.001). Moreover, AC patients had
more lymph node metastases (16 of 26) than patients with TC
(six of 41) (P  0.001). Metastatic carcinoids, either typical
or atypical, however, did not show statistically significant
differences in CD99 labeling index (20% for TCs and 15%
for ACs) and in immunostaining pattern (four tumors with
cytoplasmic immunostaining and two nonreactive in TCs,
and seven tumors with cytoplasmic immunostaining and nine
nonreactive in ACs).
In TCs/ACs, the median value of CD99 labeling index
in tumors without lymph node metastases was significantly
higher than in tumors with lymph node involvement (45%
versus 0%, respectively, P  0.0017), whereas in LCNEC/
SCLC, this difference disappeared (Fig. 3). In the former, the
median CD99 labeling index steadily decreased according to
the pN class, ranging from 45% in pN0 to 19.5% in pN1 to
0% in pN2 tumors (P  0.0016). Also a close inverse
relationship was found between the number of positive re-
gional lymph nodes and both the CD99 labeling index (r 
0.30, P  0.013) and the cytoplasmic immunostaining
pattern (r  0.29, P  0.016).
Univariate regression analysis showed that patients
with a CD99 labeling index less than 27.5% (median value),
a negative or cytoplasmic immunostaining pattern, a younger
age, decreased chromogranin A expression, and a higher
proliferative fraction were more likely to have regional lymph
node metastases (Fig. 4). Because of the high colinearity
between CD99 index and immunostaining patterns, two sep-
arate models were built to assess the risk of metastases. In
multivariate analyses adjusting for the significant variables
(i.e., age, chromogranin A and Ki-67) and a potential con-
founder (i.e., pT class), low CD99 labeling index (OR 
7.43; CI: 1.83–30.06) and nonmembranous immunostaining
pattern (OR  5.55; CI: 1.22–25.33) were independent risk
indicators for lymph node metastases in TC/AC patients (Fig.
4). In the two models, a younger age of the patients (OR 
TABLE 3. Distribution of CD99 Immunoreactivity in 136 Neuroendocrine Tumors of the Lung
CD99 labelling index CD99 immunostaining pattern  no. (%)
Tumor type Cases (pos) Median P value Neg Cyto Mem P value
TC 41 (31) 58.0% 10 (24.4) 4 (9.7) 27 (65.9)
AC 26 (14) 28.5% 12 (46.1) 14 (53.9) 0
LCNEC 42 (10) 25.0% 32 (76.2) 8 (19.0) 2 (4.8)
SCLC 27 (5) 20.0% 0.0068* 22 (81.5) 5 (18.5) 0 0.0001*
*These differences persisted after adjusting for tumor stage I (37 pIA versus 10 pIB).
pos, positive; Neg, negative; Cyto, cytoplasmic; mem, membranous; TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroendocrine carcinoma; SCLC, small
cell lung carcinoma.
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0.95; CI: 0.91–0.99 and OR  0.96; CI: 0.92–0.99, respec-
tively) and decreased chromogranin A immunoreactivity
(OR  4.89; 95% CI: 1.21–19.78 and OR  3.66 CI:
0.99–13.52, respectively) also increased the risk of lymph
node metastases. On the contrary, in LCNEC/SCLC, none of
the above parameters significantly correlated with the occur-
rence of lymph node metastases.
DISCUSSION
This investigation documents a different prevalence of
CD99 immunoreactivity and diverse staining patterns in pul-
monary neuroendocrine tumors, according to the tumor
grade, stage, and proliferative fraction. Moreover, in low- to
intermediate-grade tumors, CD99 immunoreactivity is an
independent predictor of uninvolved regional lymph nodes.
CD99 is predominantly expressed in low- to interme-
diate-grade neuroendocrine neoplasms (75.6% and 51.8%,
respectively), whereas either normal or hyperplastic endo-
crine cells of the lower respiratory tract are consistently
nonreactive for this marker. Although it is unclear why CD99
is expressed in the low-grade part of the neuroendocrine
tumor spectrum and not in the normal and hyperplastic
neuroendocrine cells, this finding is in agreement with the
general lack of CD99 immunoreactivity in several cell types
of the normal diffuse neuroendocrine system, with the pos-
sible exception of pancreatic islet cells.45 Also, CD99 is
expressed in almost 25% of well-differentiated carcinoids of
FIGURE 1. Frequency distributions of either CD99 labeling
index (A) or immunostaining patterns (B) in the whole series
of tumors as a function of tumor type, without stratifying
them for stage. A: In patients with typical carcinoid (TC) and
atypical carcinoid (TC) (shaded columns), the median values
of CD99 labeling index in the whole tumor series (n  67)
and in the positive cases only (n  45) are 27% and 45%,
respectively. In large cell neuroendocrine carcinoma/small
cell lung carcinoma (LCNEC/SCLC) (solid columns), the cor-
responding values in the total samples (n  69) and among
positive observations (n  15) are 0% and 25%, respectively
(in both series, P  0.0001). B: The membranous pattern
(open columns) prevails in TCs (n  27), the cytoplasmic
pattern (shaded columns) in ACs (n  14), and a complete
lack of any immunoreactivity (solid columns) in either LC-
NEC (n  32) or SCLC (n  22) (P  0.0001).
FIGURE 2. Distribution of CD99 immunoreactivity in differ-
ent neuroendocrine tumors of the lung. Most typical carci-
noids, with either solid trabecular (A) or spindled (B) fea-
tures, usually show strong and diffuse reactivity for CD99,
with a typical membranous labeling of tumor cells. On the
contrary, only a fraction of atypical carcinoids is reactive for
CD99, with cytoplasmic labeling (C) in fewer tumor cells
than typical carcinoids (D). Poorly differentiated large cell
neuroendocrine carcinoma (LCNEC), just like small cell lung
carcinoma (SCLC), are usually devoid of any CD99 reactivity
or show only cytoplasmic labeling in few tumor cells (E). LC-
NEC but not SCLC, however, may rarely exhibit membra-
nous pattern of immunoreactivity (F). All immunostains were
developed with diaminobenzidine and then counterstained
with hematoxylin. Scale bars are reported in the bottom on
the left of each panel.
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the gastroenteropancreatic tract,45 supporting the view that its
occurrence may be considered a feature of low-grade neu-
roendocrine tumors independently of their anatomical site. In
pulmonary TCs/ACs, the relationship between an increased
CD99 labeling index of tumor cells with membranous immu-
nostaining pattern and their grade of neuroendocrine differ-
entiation are further confirmation that CD99 expression may
be actually correlated with cell differentiation in this tumor
group (Table 4). Although there is a statistical difference
between carcinoids, either typical or atypical, and poorly
differentiated neuroendocrine carcinomas as far as CD99
labeling index and immunostaining pattern are concerned,
this marker cannot be reliably used alone in this difficult
differential diagnosis, especially in case of small tissue frag-
ments. In fact, high-grade neuroendocrine tumors of the lung
may consistently display CD99 expression, and a labeling
index dealing with membranous or cytoplasmic immuno-
staining pattern could not be easily assessable on small
crushed biopsy fragments. Therefore, the combined use of a
nuclear marker of cell proliferation, such as Ki-67 antigen
labeling index, in addition to CD99 could assist in solving
these difficult problems of differential diagnosis on small
crushed biopsies obtained during bronchoscopy.77
Although the precise functions of CD99 in pulmonary
neuroendocrine tumors remain largely unknown, a possible
role in homophilic cell-to-cell adhesion has been proposed in
other cellular systems, including normal hematopoiesis1,46
and human thymocytes,6,22 some Ewing’s sarcoma cell
lines,53 and in the binding of leukocytes to vascular endothe-
lial cells during the extravasation cascade.24,47,48 The signif-
icant inverse correlation of CD99 expression with the occur-
rence of regional lymph node metastases, increasing pN class,
the number of involved lymph nodes, and more advanced
tumor stage may well indicate for this protein a role against
the progression of neuroendocrine tumors, especially in cases
of TCs and ACs. In multivariate analysis, patients with either
low CD99 immunoreactivity (equal to or below the median
value) or purely cytoplasmic staining pattern were 7.4 and 5.5
times more likely to have lymph node metastases, respec-
tively (Fig. 4). Moreover, in the TC/AC group, the median
CD99 labeling index progressively decreased according to
the pN class, suggesting this marker could serve as a suitable
indicator of subset of patients with different risk of metasta-
ses. The significant association of CD99 expression with
tumor stage, however, disappeared after stratification for
stage I. Because low- to intermediate-grade neuroendocrine
TABLE 4. Clinicopathological Association of CD99 Labeling Index and Immunostaining Patterns in 67 Typical and Atypical
Carcinoids
Variable Category < 27%*(%) ( n  34) >27% (%) ( n  33) P value
Tumor stage I 18 (52.9) 29 (87.9)
II–III 16 (47.1) 4 (12.1) 0.0029
LN metastasis (%) Absent 18 (52.9) 28 (84.5)
Present 16 (47.1) 5 (15.1) 0.0078
LN metastasis site (%) pN0 18 (52.9) 28 (84.5)
pN1 7 (20.6) 5 (15.1)
pN2 9 (26.5) 0 0.0032
No. of positive LNs Median 1 0 0.0025
Ki-67 index Median 6.5 3 0.0134†
Calcitonin Negative 27 (79.4) 17 (51.5)
Positive 7 (20.6) 16 (48.5) 0.0214†
Neg (%) ( n  22) Cyto (%) ( n  18) Mem (%) ( n  27)
Size (cm) Median 2.4 3.5 2 0.0054
Tumor stage I 11 (50.0) 11 (61.1) 25 (92.3)
II–III 11 (50.0) 7 (38.9) 2 (7.4) 0.0032
LN metastasis (%) Absent 11 (50.0) 11 (61.1) 24 (88.9)
Present 11 (50.0) 7 (38.9) 3 (11.1) 0.0102
LN metastasis site (%) pN0 11 (50.0) 11 (61.1) 24 (88.9)
pN1 4 (18.2) 5 (27.8) 3 (11.1)
pN2 7 (31.8) 2 (11.1) 0 0.0081
No. of positive LNs Median 0.5 0 0 0.0055
Ki-67 index Median 6.9 6 2.3 0.0011†
Synaptophysin Median 80 90 100 0.0235†
Calcitonin Negative 18 (81.8) 13 (72.2) 13 (48.1)
Positive 4 (18.2) 5 (27.8) 14 (51.9) 0.0375†
Categorical variables are compared with 2 test; continuous variables with Wilcoxon’s two-sample test or Kruskal-Wallis test.
*Cutoff point corresponding to the median value of negatives and positives.
†These differences disappeared after adjusting for stage I of disease (37 cases I-A versus 10 cases I-B).
LN, lymph node; Neg, negative; Cyto, cytoplasmic; Mem, membranous.
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neoplasms are actually no considered precursors to either
LCNEC or SCLC, but separate and histogenetically unrelated
neoplasms, this peculiar distribution indicates that CD99 is
more likely to be involved in the metastatic spread (N factor)
of TCs/ACs rather than in the local growth of tumors (T
factor). Whether decreased CD99 immunoreactivity may also
favor distant metastases and thus represent a negative predic-
tor of survival cannot be derived from our data because of the
lack of adequate follow-up time. Interestingly, however, we
found that tumor emboli within vascular channels were con-
sistently nonreactive for CD99, independent of tumor type,
confirming a potential role for down-regulation of this mol-
ecule also in the development of distant metastases of pul-
monary neuroendocrine tumors (data not shown).
Recently, two isoforms of CD99 have been identified
that derive from alternative splicing of the same gene tran-
script: an Mr 32,000 long form (type I) corresponding to the
full-length protein, and a Mr 29,000 short form harboring a
deletion in the intracytoplasmic segment8,46 and recognized
by many of the antibodies reacting with the complete trans-
membrane form.9 The coordinate expression of the two iso-
forms may lead to distinct functional outcomes, thus explain-
ing the apparently contradictory properties of this molecule in
different cell models. Although distinguishing between the
two CD99 isoforms was not an aim of the current study, the
different pattern of immunostaining (either membranous or
cytoplasmic), as previously reported for gastroenteropancre-
atic carcinoids,45 suggests that there exists complex CD99
expression in different types of neuroendocrine neoplasms,
independent of their anatomical site. A definitive relationship,
however, between CD99 isoform distribution and immuno-
staining pattern cannot be derived from the data of this study.
FIGURE 3. Box plots of CD99 labeling index by the occur-
rence of regional lymph node metastases in 67 TCs/ACs (A)
and 69 LCNEC/SCLC (B) patients. All stage I patients (47
TCs/ACs and 34 LCNEC/SCLC) had by definition no lymph
node metastases, whereas those with stage I to III (20 TCs/
ACs and 35 LCNEC/SCLC) showed lymph node metastases
in all tumors but two cases of LCNEC with stage IIB corre-
sponding to pT3N0. The box is bounded below and above
by the 25% and 75% percentiles, the median is the solid
line in the box, and the lower and upper error bars indicate
the 5% and 95% percentiles, respectively. The flatness of
the boxes in the series of LCNEC/SCLC (B) is explained by
the skewness of the data toward nonexpression because ap-
proximately 78% of values are equal to zero.
0 2 4 10 20 30
p=0.005
p=0.027
p=0.420
p=0.038
p=0.018
p=0.048
p=0.007
p=0.006
CD99 index, adjusted
CD99 pattern, adjusted
pT
Chromogranin A
Ki-67 index
Age
CD99 index, unadjusted
CD99 pattern, unadjusted
 Variable Category No. of cases No Yes
 CD99 index ² 27.5% 34 18 16
 (baseline) > 27.5% 33 28 5
 CD99 pattern negative/cytoplasm 40 22 18
 (baseline) membrane 27 24 3
 pT T2-T3 18 11 7
 (baseline) T1 49 35 14
 Chromogranin A ² 95 35 20 15
 (baseline) > 95 % 34 26 6
 Ki-67 index mean (sd)  - 5.2 (4.8) 9.3 (7.3)
 Age (years) mean (sd)  - 54.8 (16.2) 45.7 (18.1)
Lymph Node Metastasis
Odds Ratio
FIGURE 4. Magnitude of odds ratios for lymph node me-
tastasis and corresponding 95% confidence intervals are
shown along the horizontal axis of the figure for each of the
potential risk factors assessed. Odds ratios, 95% confidence
intervals, and P values are generated using logistic regres-
sion. Adjusted estimates for CD99 index and CD99 pattern
were derived from separated models including pT, chromo-
granin A, Ki-67 index, and age. The six odds ratios at the
bottom of the figure represent the odds of metastasis associ-
ated with each of the six variables when regressed alone.
Variables were treated as continuous or categorical as shown
on the accompanying table.
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We found a strong positive correlation between the
CD99 labeling index and the immunostaining pattern in
neuroendocrine tumors of the lung, according to tumor type
in which the neoplasms characterized by higher (45%)
CD99 labeling index (typically TCs) showed a definite prev-
alence of the membranous pattern of staining, and the tumors
with 45% or less immunoreactive cells (typically ACs and
LCNEC/SCLC) consistently exhibited a cytoplasmic staining
pattern. This may suggest a deregulated expression of CD99
by neuroendocrine tumor cells according to their dedifferen-
tiation and malignant potential, with a down-regulation of
membrane expression and up-regulation of the cytoplasmic
expression. Our finding of increased proliferative activity in
TCs/ACs expressing cytoplasmic CD99 supports the hypoth-
esis that cytoplasmic protein may parallel the cell cycle
activity. There is evidence that CD99 may interfere with the
action of insulinlike growth factor I on cellular prolifera-
tion,55,78 as seen in several types of neuroendocrine tumors
including SCLC cell lines.79–82 Although the precise mech-
anism of this functional interaction is still elusive, the loss of
cell-cell adhesion and contact inhibition due to either down-
regulation of membrane CD99 or up-regulation of its cyto-
plasmic form may eventually promote cell cycle activation
leading to increased proliferative status and larger tumor size.
Worth mentioning is that the cytoplasmic pattern of
CD99 immunostaining in TCs/ACs was significantly associ-
ated with down-regulation of a neuroendocrine granule-re-
lated marker, such as calcitonin. As in lymphoblastoid cell
lines, the membrane expression of CD99 has been associated
with the post-Golgi trafficking machinery to cell surface,53 it
could be speculated that the membrane CD99 expression
could also be involved in granule accumulation and/or hor-
mone secretion.
In conclusion, our investigation documents that de-
creased expression of CD99 is an independent predictor of
lymph node metastasis in patients with low- to intermediate-
grade neuroendocrine tumors of the lung. Targeting the CD99
pathway could be a novel therapeutic strategy in this tumor
group in which conventional radio-/chemotherapy is largely
ineffective in the case of not radically operable disease.
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